TerraNova Capital Partners acted as Placement Agent for GBV Biopharma in its $10.5 Million Private Placement
Series A Preferred Stock & Common Stock Warrants
GVB Biopharma the International hemp technology company is at the vanguard of the organic cultivation, research, development, and marketing of hemp-based wellness solutions, has closed a $10.5 million private placement with certain investors. The private placement consisted of 5.25 million shares of A Preferred stock at the purchase price of $2.00 per share with a 5% dividend.
TerraNova Capital Partners acted as placement agent for the offering.
About GBV Biopharma, Inc.
GVB is one of the world’s leading innovators in hemp technology. GVB is at the vanguard of the organic cultivation, research, development, and marketing of hemp-based wellness solutions for suppliers, customers, and consumers around the globe. The Company prioritizes cannabinoid research, industry innovation, and traceable quality control. GVB operates two state-of-the-art facilities: a 30,000-square-foot food-grade hemp processing facility in Central Oregon and a 40,000-square-foot white-label consumer product manufacturing facility in Las Vegas. The Company’s work changes lives for the better. For more information on GVB Biopharma please visit www.gvbbiopharma.com.
About TerraNova Capital Partners
TerraNova is a boutique investment, merchant banking and advisory firm focused on small-to-middle market companies. TerraNova Capital Equities, the investment bank, provides financial and capital solutions, while TerraNova Capital Partners focuses on merger and acquisition (M&A) advice and finance and merchant banking. The name means New Earth or New World. The firm’s goal is to back companies that save the Earth and create a better New World. For more information on TerraNova please visit www.terracap.com.